Background and Objectives: This study reports a case of a 62-year-old patient experiencing a significant decline in vision over the past three months. The initial best-corrected visual acuity (BCVA) of 20/20 in both eyes diminished to 20/200 in the right eye (RE) and counting fingers (CF) in the left eye (LE) within this timeframe. The patient was diagnosed with stage 4 ovarian cancer just one month before the significant vision deterioration. Materials and Methods: A thorough ophthalmologic examination revealed a notable progression of cataracts and the presence of subretinal fluid on the posterior pole, accompanied by choroidal thickening. The right eye exhibited multifocal, orange-pigmented, and elevated choroidal lesions, while the left eye’s fundus examination was impeded by dense cataracts. Optical coherence tomography (OCT) revealed bilateral choroidal thickening with overlying folds and subretinal fluid, and ultrasound imaging of the choroidal lesions indicated moderate homogenous internal reflectivity. Results: The patient received a diagnosis of BDUMP (bilateral diffuse uveal melanocytic proliferation), a paraneoplastic syndrome marked by simultaneous, bilateral, painless vision loss and the rapid onset of bilateral cataracts with serous retinal detachments. Despite cataract extraction, the expected visual recovery was not achieved (RE: CF; LE: 2/200, respectively). Plasmapheresis showed some success in stabilizing vision loss attributed to serous retinal detachments. Conclusions: BDUMP necessitates addressing the underlying malignancy for effective treatment. Left untreated, it can lead to near blindness within a year. The prognosis remains grim, with an average survival time ranging from 12 to 15.7 months from the time of diagnosis. Considering this case report, it is crucial to establish effective management plans and further investigate potential treatment methods and predictive markers centered around BDUMP. Collaboration between healthcare professionals and researchers is crucial in addressing the complexities of BDUMP, as the timely diagnosis and treatment of the disease remains a top priority.

Corneal confocal microscopy (CCM) is a non-invasive imaging technique that enables quantification of the corneal sub-basal nerve plexus and has emerged as a potential surrogate biomarker for peripheral neurodegeneration. This scoping review evaluated current evidence on the use of CCM in assessing corneal nerve fibre changes across neurodegenerative diseases (NDDs) and explored its potential as a paraclinical diagnostic and monitoring tool. A comprehensive search of PubMed and Scopus was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines to identify studies reporting quantitative CCM metrics, including corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fibre length (CNFL). Both cross-sectional and longitudinal studies of patients with NDDs were included, and findings were narratively synthesised. 50 studies were included: Parkinson’s disease (n=13), multiple sclerosis (n=11), cerebrovascular accidents (n=7), post-COVID-19 neuropathy (n=5), amyotrophic lateral sclerosis (n=4), chronic inflammatory demyelinating polyneuropathy (n=4), Alzheimer’s disease (n=3), Fabry disease (n=2) and neurofibromatosis type 1 (n=1). CNFL and CNFD were consistently reduced in Parkinson’s disease, multiple sclerosis, cerebrovascular accidents, amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy and post-COVID-19 neuropathy, whereas CNBD results were inconsistent. The strongest evidence supported the role of CCM in Parkinson’s disease and multiple sclerosis. CNFL and CNFD emerged as the most reliable CCM-derived metrics across NDDs, supporting their potential as objective biomarkers for neurodegeneration. While findings support the potential of CCM as a paraclinical diagnostic tool, methodological heterogeneity in image acquisition, analysis software and study design limited comparability. Standardised imaging and analysis protocols are needed to enable broader clinical application and validation across NDDs.

Background and Objectives: A 62-year-old patient presented with significant visual reduction in the last three months. Best corrected visual acuity (BCVA) of the right eye (RE) dropped from 20/20 on both eyes to 20/200 on the RE and counting fingers (CF) on the left eye (LE); respectfully. She was diagnosed with stage 4 ovarian cancer 1 month ago. Materials and Methods: Examination revealed significant progression of cataracts and subretinal fluid on the posterior pole with choroidal thickening. Multifocal, orange-pigmented elevated choroidal lesions were observed in the RE, while the view of the left eye fundus was obstructed by cataracts. OCT revealed bilateral choroidal thickening with overlying folds and subretinal fluid and ultrasound of the choroidal lesions showed moderate homogenous internal reflectivity. Results: The patient was diagnosed with BDUMP (bilateral diffuse uveal melanocytic proliferation), a paraneoplastic syndrome characterised by simultaneous, bilateral, painless vision loss and rapidly acquired bilateral cataracts with serous retinal detachments. Cataract extraction had not obtained the expected visual recovery (RE: CF; LE 2/200, respectfully). Plasmapheresis demonstrated some success by stabilizing vision loss obtained by serous retinal detachments. Conclusion: The focus of treating BDUMP is aimed at the underlying malignancy. Vision typically deteriorates to near blindness within a year from presentation. Overall prognosis is generally poor and mean survival is reported at 12-15.7 months from the time of ocular diagnosis.

Background and Objectives: Predicting postoperative refractive development after paediatric intraocular lens (IOL) implantation remains challenging due to continued ocular growth and interindividual variability. This scoping review maps current evidence on demographic, biometric, and surgical factors influencing postoperative myopic shift in children undergoing cataract surgery with IOL implantation. Methods and Materials: A systematic literature search was conducted in PubMed and Scopus from the last ten years through October 2025. Eligible studies included children (≤18 years) with congenital or developmental cataract undergoing primary or secondary IOL implantation that reported postoperative refractive change and its predictors. Titles, abstracts, and full texts were screened according to PRISMA-ScR guidelines. Data were charted on study design, age at surgery, follow-up duration, refractive and biometric outcomes, and associated predictors. Results: Twelve studies met the inclusion criteria. Younger age at surgery, shorter preoperative axial length, and unilateral cataract consistently predicted greater postoperative myopic shift. Reported myopic change ranged from approximately −1.8 D after 2 years to −11.6 D after 15 years of follow-up, correlating with the rate of axial elongation. Optical biometry and modern formulas (e.g., Holladay 1) showed lower absolute prediction error than manual A-scan or SRK-II calculations. Postoperative complications, especially glaucoma and visual axis opacification, were associated with greater refractive change. Conclusions: Postoperative myopic shift is a predictable, age-dependent feature of paediatric pseudophakia driven primarily by ocular growth dynamics. Standardised biometry, age-stratified refractive targeting, and integration of longitudinal growth models into IOL calculation algorithms may improve refractive predictability and visual outcomes in children.

Thyroid-associated orbitopathy is an autoimmune inflammatory disorder of the orbit associated with autoimmune thyroid disease. Autoimmune-mediated inflammation leads to the expansion of retrobulbar adipose tissue and extraocular muscles. This initiates a vicious cycle of progressive morphologic and functional orbital changes. Patients experience a variety of symptoms. Eyelid retraction, globe proptosis, erythema, and edema of periorbital soft tissues affect patients' appearance. Diplopia is a result of extraocular muscle changes. Corneal and optic nerve involvement represent vision-threatening complications. Reliance solely on clinical assessment is insufficient in differentiating between active inflammatory disease and inactive fibrotic stages. Imaging methods – ultrasound, computed tomography, and magnetic resonance imaging – are used in the assessment of the disease. Nowadays, optical coherence tomography has shown promise in evaluating disease activity in thyroid-associated orbitopathy by assessing choroidal parameters alongside retinal nerve fiber layer thickness, which may precede clinical signs of compressive optic neuropathy. Treatment modalities vary according to the phase of the disease. Corticosteroid therapy remains the first-line treatment for moderate-to-severe active disease. Teprotumumab (Tepezza), a monoclonal antibody targeting the insulin-like growth factor-1 receptor, has demonstrated superior clinical outcomes in reducing proptosis, diplopia, and disease activity, even in patients with long-standing disease. Botulinum toxin is used in the active phase of the disease to improve diplopia and abnormal head position. Surgical procedures represent the treatment of choice after the disease has entered the inactive phase, for patients with residual proptosis, diplopia, and strabismus, or for the improvement of eyelid malposition and function.

Purpose: This case series investigated and elucidated various retinal pathologies observed in patients with COVID-19 infection. We sought to understand the prevalence and manifestations of these conditions by exploring the link between COVID-19 and retinal pathologies. Methods: We conducted a retrospective analysis of patients diagnosed with COVID-19 who subsequently exhibited retinal pathologies. Medical records and ophthalmic imaging data were thoroughly reviewed to identify specific cases of central serous chorioretinopathy (CSCR), paracentral acute middle maculopathy (PAMM), bilateral Krill’s disease, and vessel occlusion. Results: Our analysis revealed a spectrum of retinal pathologies in patients with COVID-19 infection. These included CSCR, PAMM, bilateral Krill’s disease, and central retinal artery occlusion. These pathologies appear to be closely associated with the inflammatory and thrombotic effects of the virus on the retina. Conclusion: This case series demonstrates the importance of recognising and promptly managing retinal pathologies in individuals recovering from COVID-19 to mitigate vision loss. Although our findings suggest a strong connection between these ophthalmic manifestations and COVID-19 infection, further research is warranted to establish a definitive correlation and expand our understanding of these conditions in the context of post-COVID-19 recovery.